Drotaverine Hydrochloride

Dot is indicated in gastric spasm, intestinal spasm or pyloric spasm, cholelithiasis and spastic constipation, to relieve tenesmus in dysentry, dysmenorrhoea, peripheral vascular disorders. Owing to its freedom from cardiotoxic and hypotensive effects, Dot has outstanding value in the treatment of coronary insufficiency and angina pectoris.

Drotaverine HCl is a new potent synthetic antispasmodic drug which is readily absorbed from the intestine. Like papaverine, it acts directly on the smooth muscle fibers exceeding however, the antispasmodic effect of the standard preparations. Drotaverine HCl is characterized by its rapid onset of actions which has advantage in cases of acute painful spastic conditions. In addition to its spasmolytic and vasodilatory actions, Drotaverine HCl elicits a selective blockage of cardiac beta-receptors.

The usual dose for adults is 1 to 2 tablets three times daily, one to three times 2 to 4 ml injection subcutaneously or intramuscularly. In case of acute stone colic 2 to 4 ml may be given by slow intravenous injection, in case of peripheral arterial spasm or obstruction Drotaverine HCl may be injected intra arterially. Children should be given smaller doses according to age and body weight. Children should receive once or twice daily 1/4 to 1/2 tablet, adolescent 1/2 to 1 tablet daily. In peptic ulcer it is expedient to combine Drotaverine HCl with atropine or atropine-like compounds.